The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

Global estimates on the number of persons across the Alzheimer's disease continuum

(2022) Anders Gustavsson et al.   Alzheimers & Dementia

Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level

(2022) Annette Langer‐Gould et al.   ANNALS OF NEUROLOGY

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

(2022) Oskar Hansson et al.   Alzheimers & Dementia

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Costs of Dementia in Europe: An Updated Review and Meta-analysis

(2022) Linus Jönsson et al.   PHARMACOECONOMICS

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

The costs of developing treatments for Alzheimer's disease: A retrospective exploration

(2021) Jeffrey L. Cummings et al.   Alzheimers & Dementia

Leaving no one behind: health equity as a catalyst for the sustainable development goals

(2020) Tatjana Buzeti et al.   EUROPEAN JOURNAL OF PUBLIC HEALTH

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

(2019) Stéphane Epelbaum et al.   BMJ Open

Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia

(2017) Steven G. Morgan et al.   HEALTH POLICY

Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study

(2010) Anders Gustavsson et al.   Journal of Nutrition Health & Aging

The NICE Cost-Effectiveness Threshold

(2008) Christopher McCabe et al.   PHARMACOECONOMICS